NCT04810091
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Recruiting
Phase 3
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be currently receiving stable-dose somatostatin analog (SSA) therapy
Exclusions: Patients with previous exposure to telotristat ethyl (Xermelo)
https://ClinicalTrials.gov/show/NCT04810091